SCHEMBL1680508

SCHEMBL1680508

O=C(NCc1cccc(OCc2ccccc2)c1)c1ccc2ncccc2c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.55
ALDH1A1 P00352 2/20 0.55
LMNA P02545 2/20 0.55
KDM4E B2RXH2 1/20 0.55
MAPT P10636 1/20 0.55
MAPK1 P28482 1/20 0.55
NPC1 O15118 2/20 0.54
CYP2D6 P10635 2/20 0.54
CYP2C9 P11712 2/20 0.54
CYP1A2 P05177 1/20 0.54
CYP2C19 P33261 1/20 0.54
SENP1 Q9P0U3 2/20 0.53
MMP13 P45452 1/20 0.53
SPHK2 Q9NRA0 3/20 0.52
SPHK1 Q9NYA1 1/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
SMPD1 P17405 1/20 0.51
CYP3A4 P08684 2/20 0.50
BCAT1 P54687 1/20 0.50
ROCK2 O75116 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13491444 0.94 RAB9A (0.55) RAB9AALDH1A1LMNAKDM4EMAPT
SCHEMBL13491471 0.92 EGLN1 (0.54) RAB9AALDH1A1LMNAKDM4EMAPT
SCHEMBL13491447 0.91 LMNA (0.61) RAB9AALDH1A1LMNAMAPTNPC1
SCHEMBL1680422 0.90 HDAC1 (0.60) RAB9AALDH1A1LMNAKDM4EMAPT
SCHEMBL1681262 0.90 FFAR1 (0.57) LMNAMMP13SMN1; SMN2CYP3A4ROCK2
SCHEMBL13491592 0.90 EGLN1 (0.57) RAB9AALDH1A1LMNAKDM4EMAPT
SCHEMBL13491502 0.90 ROCK2 (0.52) RAB9AALDH1A1LMNAKDM4EMAPT
SCHEMBL13491412 0.89 ROCK2 (0.51) RAB9AALDH1A1LMNAKDM4EMAPT
SCHEMBL13002987 0.88 ROCK2 (0.65) RAB9AALDH1A1LMNAKDM4EMAPT
SCHEMBL13491469 0.88 RAB9A (0.50) RAB9AALDH1A1LMNAKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110195999-A1 NOVEL ANTIFUNGAL AGENT CONTAINING HETEROCYCLIC COMPOUND NAKAMOTO KAZUTAKA 2011-08-11 US disclosed
US-20110195999-A1 NOVEL ANTIFUNGAL AGENT CONTAINING HETEROCYCLIC COMPOUND NAKAMOTO KAZUTAKA 2011-08-11 US disclosed
US-20110195999-A1 NOVEL ANTIFUNGAL AGENT CONTAINING HETEROCYCLIC COMPOUND NAKAMOTO KAZUTAKA 2011-08-11 US disclosed
US-7932272-B2 Antifungal agent containing heterocyclic compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2011-04-26 US disclosed
US-7932272-B2 Antifungal agent containing heterocyclic compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2011-04-26 US disclosed
US-7932272-B2 Antifungal agent containing heterocyclic compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2011-04-26 US disclosed
US-20090227799-A1 Novel Antimalarial Agent Containing Heterocyclic Compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-09-10 US disclosed
US-20070105943-A1 Novel antifungal agent containing heterocyclic compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2007-05-10 US disclosed
US-20070105943-A1 Novel antifungal agent containing heterocyclic compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2007-05-10 US disclosed
US-20070105943-A1 Novel antifungal agent containing heterocyclic compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2007-05-10 US disclosed
EP-1782811-A1 NOVEL ANTIMALARIA AGENT CONTAINING HETEROCYCLIC COMPOUND Eisai R&D Management Co., Ltd. (JP) 2007-05-09 EP disclosed
EP-1669348-A1 NOVEL ANTIFUNGAL AGENT COMPRISING HETEROCYCLIC COMPOUND Eisai Co., Ltd. (JP) 2006-06-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110195999-A1 NOVEL ANTIFUNGAL AGENT CONTAINING HETEROCYCLIC COMPOUND ERG28, CYP51A1, XPO1 RAB9A 1844/4885ALDH1A1 1677/4885LMNA 2372/4885
US-20090227799-A1 Novel Antimalarial Agent Containing Heterocyclic Compound XPO1, THPO, G6PD RAB9A 391/4885ALDH1A1 1926/4885LMNA 698/4885
US-20070105943-A1 Novel antifungal agent containing heterocyclic compound ERG28, DPM1, CYP51A1 RAB9A 1739/4885ALDH1A1 1459/4885LMNA 2208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.